Indian J Pharm Close
 

Table 9: Question 3 (ii): What is the appropriate choice of therapy for HR +ve/ Her2−ve breast cancer in the presence of significant visceral disease in the first‑line metastatic setting

Table 9: Question 3 (ii): What is the appropriate choice of therapy for HR +ve/ Her2−ve breast cancer in the presence of significant visceral disease in the first‑line metastatic setting